---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-356877"
form_type: "8-K"
ticker: "KRRO"
cik: "0001703647"
company_name: "Korro Bio, Inc."
filed_at: "2026-08-19T20:05:15+00:00"
generated_at: "2026-08-19T20:06:11.255097+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Korro Bio submits to Australian ethics committee to begin Phase 1/2 trial for KRRO-121 in UCDs

## Summary
- Submission to Alfred Health Human Ethics Committee to start first-in-human Phase 1/2 trial of KRRO-121.
- KRRO-121 is a GalNAc-conjugated RNA editing oligonucleotide targeting hyperammonemia in Urea Cycle Disorders.
- Trial will evaluate safety, tolerability of escalating doses, and pharmacokinetics in healthy volunteers and UCD patients.
- Listed on ClinicalTrials.gov as NCT07773246.
- No clinical data released yet; first-in-human milestone for the program.

## SEC filing metadata
- accession: 0001193125-26-356877
- form_type: 8-K
- ticker: KRRO
- cik: 0001703647
- company_name: Korro Bio, Inc.
- filed_at: 2026-08-19T20:05:15+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1703647/000119312526356877/0001193125-26-356877-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1703647/000119312526356877/krro-20260819.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-356877
- JSON: https://secwatch.observer/filing/0001193125-26-356877.json
- Plain text: https://secwatch.observer/filing/0001193125-26-356877.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.